Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)

Last updated: July 25, 2024
Sponsor: Peking University Third Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gall Bladder Cancer

Liver Cancer

Primary Biliary Cholangitis

Treatment

N/A

Clinical Study ID

NCT06277531
IRB00006761-M2024086
  • Ages 18-85
  • All Genders

Study Summary

Biliary stricture is mainly malignant in the adults and caused by several types of fatal malignancies such as pancreatic cancer, cholangiocarcinoma, and metastatic tumor, which have poor prognosis that the overall survival of unresectable lesions is no more than 15 months. The poor outcome often relates to a lack of reliable strategies for early diagnosis, which results in most patients with malignant biliary stricture being already advanced-stage disease at presentation. Therefore, it is critical to discover novel and effective strategies for the early diagnosis of malignant biliary strictures.

Brush cytology and biopsy during endoscopic retrograde cholangiopancreatography (ERCP) are the main methods for recognizing malignant diseases of the bile duct, but their sensitivity is relatively low, 45% and 48.1%, respectively. Even when combined with other biomarkers like carbohydrate antigen 19-9 (CA19-9), their sensitivity is still less than 80%.

In the previous study, the investigators found that bcf-eccDNA has excellent diagnostic value in predicting uncertain bile duct stricture, and the sensitivity and specificity of a related eccDNA in 40 samples are 80.8% and 100%. The sensitivity and specificity of another eccDNA were 92.3% and 92.9%, respectively. However, the sample size is still relatively small, and further prospective studies are needed to evaluate its diagnostic efficacy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients is suspected indetermined biliary strictures

  • Patients have the indication for ERCP

Exclusion

Exclusion Criteria:

  • ERCP failed, or can not obtain bile

  • Sever comorbidities

  • Predicted overall survival less than 1 year because of other disease

  • Patients who are unlikely to comply with the protocol, inability to return forsubsequent visits

Study Design

Total Participants: 99
Study Start date:
March 01, 2024
Estimated Completion Date:
March 01, 2027

Connect with a study center

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing 102218
    China

    Active - Recruiting

  • Peking University Third Hospital

    Beijing, Beijing 1000191
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.